Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;28(3):133-9.
doi: 10.1293/tox.2015-0031. Epub 2015 Jun 15.

Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies

Masami Suzuki  1 , Chie Kato  1 , Atsuhiko Kato  1
Affiliations
Review

Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies

Masami Suzuki et al. J Toxicol Pathol. 2015 Jul.

Erratum in

  • Errata (Printer's correction).
    [No authors listed] [No authors listed] J Toxicol Pathol. 2016 Jan;29(1):74. Epub 2016 Feb 17. J Toxicol Pathol. 2016. PMID: 26989306 Free PMC article.

Abstract

Antibodies can swiftly provide therapeutics to target disease-related molecules discovered in genomic research. Antibody engineering techniques have been actively developed and these technological innovations have intensified the development of therapeutic antibodies. From the mid-1990's, a series of therapeutic antibodies were launched that are now being used in clinic. The disease areas that therapeutic antibodies can target have subsequently expanded, and antibodies are currently utilized as pharmaceuticals for cancer, inflammatory disease, organ transplantation, cardiovascular disease, infection, respiratory disease, ophthalmologic disease, and so on. This paper briefly describes the modes of action of therapeutic antibodies. Several non-clinical study results of the pathological changes induced by therapeutic antibodies are also presented to aid the future assessment of the toxic potential of an antibody developed as a therapeutic.

Keywords: mode of action; pathological findings; therapeutic antibody; toxicity study.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Mechanisms of action of therapeutic antibodies.
See this image and copyright information in PMC

References

    1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, and de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 12: 615–622. 2012. - PubMed
    1. Emmons C, and Hunsicker LG. Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med. 77: 78–82. 1987. - PubMed
    1. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc. 19(Suppl 1): 1–6. 1987. - PubMed
    1. Morrison SL, Johnson MJ, Herzenberg LA, and Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 81: 6851–6855. 1984. - PMC - PubMed
    1. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 58: 640–656. 2006. - PubMed